Literature DB >> 34647186

Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes.

Sergio Gonzalez1, Pablo Uribe2,3, Cristian Navarrete-Dechent4,5, Matias Gompertz-Mattar2, Juan Perales2, Aditi Sahu6, Sebastián Mondaca7,3.   

Abstract

Few studies have evaluated programmed cell death ligand (PD-L1) expression and lymphocytic infiltrates in Basal Cell Carcinoma (BCC). The objectives of this study are to assess PD-L1 expression and markers of local immune response in nodular, superficial, and morpheaform BCC, and compare it to normal, sun-exposed skin from the periphery of intradermal nevi. This was a retrospective study that included three histological subtypes of BCCs, and sun-exposed skin from the periphery of dermal nevi as quality controls. Tissue microarrays (TMA) were constructed with subsequent staining of H&E and immunohistochemistry (IHC) for CD4, CD8, FOXP3 and PD-L1. Non-automated quantification of the infiltrate in the intratumoral and stromal compartments on TMAs was performed. A total of 115 BCC (39 nodular, 39 morpheaform, and 37 superficial) and 41 sun-exposed skin samples were included (mean age 65.4 years; 52.6% females). BCC showed higher expression of PD-L1 (5.4 vs 0.7%, p < 0.001), CD8 (29.8 vs 19.7%, p = 0.002), and FOXP3 (0.3 vs 0.06%, p = 0.022) compared to sun-exposed skin. There was a higher PD-L1 expression in nodular BCC compared with other subtypes. Low-risk BCC subtypes (superficial and nodular) exhibited more PD-L1 expression in intratumoral and stromal immune infiltrates as compared to high-risk BCC subtypes. As a limitation, no immune cells function was evaluated in this study, only the presence/absence of T-lymphocyte sub-populations was recorded. Substantial differences in both PD-L1 expression and lymphocytic infiltrates were found amongst the histological subtypes of BCC and sun-exposed skin. Highest PD-L1 expression was found in nodular BCCs which suggests a potentially targetable strategy in the treatment of this most common BCC subtype.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Basal cell carcinoma; Diagnosis; Immunohistochemistry; Immunotherapy; Lymphocytes; PD-1; PD-L1; Programmed cell death ligand 1; Stains

Mesh:

Substances:

Year:  2021        PMID: 34647186     DOI: 10.1007/s00403-021-02289-w

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.033


  51 in total

1.  Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study.

Authors:  Gary Goldenberg; Tom Karagiannis; Jacqueline Blanche Palmer; Juzer Lotya; Caitriona O'Neill; Renata Kisa; Vivian Herrera; Daniel M Siegel
Journal:  J Am Acad Dermatol       Date:  2016-07-26       Impact factor: 11.527

2.  Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.

Authors:  Howard W Rogers; Martin A Weinstock; Steven R Feldman; Brett M Coldiron
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

Review 3.  Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations.

Authors:  Michael C Cameron; Erica Lee; Brian P Hibler; Christopher A Barker; Shoko Mori; Miguel Cordova; Kishwer S Nehal; Anthony M Rossi
Journal:  J Am Acad Dermatol       Date:  2018-05-18       Impact factor: 11.527

4.  Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.

Authors:  Gery P Guy; Steven R Machlin; Donatus U Ekwueme; K Robin Yabroff
Journal:  Am J Prev Med       Date:  2014-11-10       Impact factor: 5.043

5.  Vismodegib.

Authors:  Charles M Rudin
Journal:  Clin Cancer Res       Date:  2012-06-07       Impact factor: 12.531

Review 6.  Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.

Authors:  Mohd Wahid; Arshad Jawed; Raju K Mandal; Sajad A Dar; Saif Khan; Naseem Akhter; Shafiul Haque
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-21       Impact factor: 6.312

7.  Basal cell carcinoma does metastasize.

Authors:  Doruk Ozgediz; E B Smith; Jie Zheng; Jose Otero; Z Laura Tabatabai; Carlos U Corvera
Journal:  Dermatol Online J       Date:  2008-08-15

8.  Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect?

Authors:  M Staples; R Marks; G Giles
Journal:  Int J Cancer       Date:  1998-10-05       Impact factor: 7.396

9.  A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.

Authors:  Dawn Odom; Deirdre Mladsi; Molly Purser; James A Kaye; Eirini Palaka; Alina Charter; Jo Annah Jensen; Dalila Sellami
Journal:  J Skin Cancer       Date:  2017-05-21

Review 10.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.

Authors:  Shalini V Mohan; Anne Lynn S Chang
Journal:  Curr Dermatol Rep       Date:  2014-02-09
View more
  2 in total

1.  Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.

Authors:  Gino Kim In; Aparna Nallagangula; Jacob Seung Choi; Lisa Tachiki; Matthew J Blackburn; Stephen Capone; Kathryn B Bollin; Daniel Y Reuben; Keisuke Shirai; Sandy Zhang-Nunes; Omar Ragab; Alicia Terando; Jenny C Hu; Han Lee; Shailender Bhatia; Sunandana Chandra; Jose Lutzky; Geoffrey Thomas Gibney
Journal:  J Immunother Cancer       Date:  2022-05       Impact factor: 12.469

2.  Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas.

Authors:  Uffe Høgh Olesen; Martin Wiinberg; Catharina Margrethe Lerche; Ditte Elisabeth Jæhger; Thomas Lars Andresen; Merete Haedersdal
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.